CG Oncology, Inc. (CGON) - Cash per Single Share

Anticipation of the Phase 3 gene therapy trial results and development costs are already priced into CG Oncology, Inc. (CGON) quotes. The historical cash per share level helps assess the issuer's financial resilience, where 11.01 is recorded as the baseline value. CG Oncology, Inc. (CGON) leads the field of oncolytic immunotherapy by creating bioengineered viruses. The application of such drugs against bladder cancer provides a competitive market advantage.
Comprehensive metric breakdowns and analytics for cgoncology.com (CGON)

This indicator measures the ratio of liquid reserves to the total number of shares, allowing for the rapid identification of equity dilution between quarterly reports. By analyzing the history of cash per share, an investor assesses the financial stability of CG Oncology, Inc. (CGON), whose significant pricing power in the inelastic demand segment for oncolytic therapy requires efficient capital management to sustain the pace of innovation.